| Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy SL Shiao, KM Kershaw, JJ Limon, S You, J Yoon, EY Ko, J Guarnerio, ... Cancer cell 39 (9), 1202-1213. e6, 2021 | 131 | 2021 |
| Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas HC Kang, HK Kim, S Lee, P Mendez, JW Kim, G Woodard, JH Yoon, ... Oncotarget 7 (7), 8321, 2016 | 56 | 2016 |
| 27-hydroxycholesterol impairs plasma membrane lipid raft signaling as evidenced by inhibition of IL6–JAK–STAT3 signaling in prostate cancer cells S Dambal, M Alfaqih, S Sanders, E Maravilla, A Ramirez-Torres, ... Molecular Cancer Research 18 (5), 671-684, 2020 | 46 | 2020 |
| Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target JH Jung, S You, JW Oh, J Yoon, A Yeon, M Shahid, E Cho, V Sairam, ... Cancer letters 437, 1-12, 2018 | 27 | 2018 |
| A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer YJ Jan, J Yoon, JF Chen, PC Teng, N Yao, S Cheng, A Lozano, GCY Chu, ... Theranostics 9 (10), 2812-2826, 2019 | 23 | 2019 |
| Development of a robust DNA quality and quantity assessment qPCR assay for targeted next-generation sequencing library preparation J Dang, P Mendez, S Lee, JW Kim, JH Yoon, TW Kim, CJ Sailey, ... International journal of oncology 49 (4), 1755-1765, 2016 | 19 | 2016 |
| A comparative study of PCS and PAM50 prostate cancer classification schemes J Yoon, M Kim, EM Posadas, SJ Freedland, Y Liu, E Davicioni, RB Den, ... Prostate cancer and prostatic diseases 24 (3), 733-742, 2021 | 17 | 2021 |
| Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential ET Miller, S You, RM Cadaneanu, M Kim, J Yoon, ST Liu, X Li, L Kwan, ... BMC cancer 20, 1-15, 2020 | 17 | 2020 |
| Biologic significance of magnetic resonance imaging invisibility in localized prostate cancer SS Salami, JB Kaplan, S Nallandhighal, M Takhar, JJ Tosoian, M Lee, ... JCO Precision Oncology 3, 1-12, 2019 | 16 | 2019 |
| Comprehensive evaluation and validation of targeted next-generation sequencing performance in two clinical laboratories P Mendez, J Dang, JW Kim, S Lee, JH Yoon, T Kim, CJ Sailey, ... International Journal of Oncology 49 (1), 235-242, 2016 | 11 | 2016 |
| Loss of the tumor suppressor, TP53, enhances the androgen receptor mediated oncogenic transformation and tumor development in the mouse prostat ZS Yongfeng He, Daniel T. Johnson, Julie S. Yang, Huiqing Wu, Sungyong You ... Oncogene, 2019 | 7 | 2019 |
| Mobile Genome Express (MGE): A comprehensive automatic genetic analyses pipeline with a mobile device JH Yoon, TW Kim, P Mendez, DM Jablons, IJ Kim Plos one 12 (4), e0174696, 2017 | 4 | 2017 |
| Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. Oncotarget. 2016; 7 (7): 8321-31 HC Kang, HK Kim, S Lee, P Mendez, W Kim, G Woodard, JH Yoon, ... | 4 | |
| Development of a circulating tumor cell-based RNA classifier for patients with castration-resistant prostate cancer: CTC-PCS/PAM50. PC Teng, YJ Jan, M Kim, JF Chen, J Yoon, JJ Wang, PJ Chen, N Yao, ... Journal of Clinical Oncology 38 (15_suppl), e17509-e17509, 2020 | 1 | 2020 |
| A circulating tumor cell specific RNA assay for assessment of androgen receptor signaling inhibitor sensitivity in metastatic castration-resistant prostate cancer. PC Teng, YJ Jan, J Yoon, PJ Chen, JF Chen, N Yao, S Cheng, A Lozano, ... Journal of Clinical Oncology 37 (15_suppl), 5059-5059, 2019 | 1 | 2019 |
| Methods and systems for detection of a genetic mutation IJ Kim, D Jablons, PJM Romero, Y Jun-Hee US Patent App. 14/867,934, 2016 | 1 | 2016 |
| GEE: An Informatics Tool for Gene Expression Data Explore SY Lee, CH Park, JH Yoon, S Yun, JH Kim Healthcare informatics research 22 (2), 81, 2016 | 1 | 2016 |
| NUAK2 inhibition for prostate cancer. W Fu, M Zhao, A Schirmer, EJ Maravilla, J Yoon, S You, SJ Freedland, ... MOLECULAR CANCER RESEARCH 18 (8), 46-46, 2020 | | 2020 |
| Characterization of the global proteome and phosphoproteome in cisplatin-resistant bladder cancers revealed the CDK2 network as a potential therapeutic target. JH Jung, S You, JW Oh, J Yoon, A Yeon, M Shahid, E Cho, V Sairam, ... CLINICAL CANCER RESEARCH 26 (15), 53-53, 2020 | | 2020 |
| Abstract B13: Characterization of the global proteome and phosphoproteome in cisplatin-resistant bladder cancers revealed the CDK2 network as a potential therapeutic target JH Jung, S You, JW Oh, J Yoon, A Yeon, M Shahid, E Cho, V Sairam, ... Clinical Cancer Research 26 (15_Supplement), B13-B13, 2020 | | 2020 |
